Murine adrenal cortex tumor Y-1 cells contained both soluble and particulate forms of cyclic nucleotide phosphodiesterase (3′,5′-cyclic AMP 5′-nucleotide hydrolase, EC 188.8.131.52). The soluble forms of the enzyme comprised 80% of total cellular phosphodiesterase activity. The soluble enzyme(s) hydrolyzed both cyclic AMP and cyclic GMP, with apparent Km values of 125 and 30 μm, respectively. Soluble cyclic AMP phosphodiesterase showed marked inhibition by the calcium chelator, ethylene glycol bis(β-aminoethyl ether)-N,N′-tetraacetic acid (EGTA), and the anticalmodulin drugs, chlorpromazine, N-(6-aminohexyl)-5-chloro-1-naphthalenesulfonamide (W-7), and calmidazolium. No alteration in soluble cyclic GMP phosphodiesterase activity was observed when cyclic AMP was added to the assay. Resolution of the soluble enzymatic activity by DEAE-cellulose chromatography in the presence of calcium showed two peaks of phosphodiesterase activity. Further purification of one of these peaks on DEAE-cellulose in the presence of EGTA yielded a phosphodiesterase activity peak that was stimulated fivefold by calmodulin. The particulate form of the enzyme hydrolyzed both cyclic AMP and cyclic GMP; the apparent Km values for these substrates were similar (90 and 100 μm, respectively). Hydrolysis of cyclic GMP by the particulate enzyme was inhibited by cyclic AMP in a concentration-dependent manner with an apparent half-maximal inhibitory concentration of 100 μm. The particulate form of phosphodiesterase was not inhibited by EGTA or anticalmodulin drugs.
|Original language||English (US)|
|Number of pages||10|
|Journal||Archives of Biochemistry and Biophysics|
|State||Published - Sep 1985|
Bibliographical noteFunding Information:
’ This work was supported in part by a grant from the National Institutes of Health, GM-28897. WAT is a fellow of the Mellon Foundation. *To whom all correspondence should be addressed. ’ Abbreviations used: ACTH, adrenocorticotropic hormone; CaM, calmodulin; DTT, dithiothreitol; EGTA, ethylene glycol his@-aminoethyl ether)-N,N’tetraacetic acid; IC., half-maximal inhibitory concentration; PhMeSOBF, phenylmethylsulfonyl fluoride; W-5, N-(6-aminohexyl)-l-naphthalenesulfon- amide; W-7, N-(6-aminohexyl)-5-chloro-l-naphtha- lenesulfonamide.